Frazier Life Sciences — 2016 Investments
5 investments dated 2016 · listed companies and verified rows first · show all
Alcresta Therapeutics develops enzyme-based therapeutic products to address nutritional care for enterally fed patients living with rare diseases.
BiotechHealthtechMedical DevicesMassachusetts, US
Daniel Orlando(Chief Executive Officer)Jeremy Lack(Director)Stephen Krauss(Director)Tasos Konidaris(Executive Officer)James Topper(Director)Steve Dubin(Director)
Board seatJames N. Topper· per SEC Form D
BiotechEvanston, US
Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Liam Ratcliffe(Director)Ashish Khanna(Secretary & Chief Business Officer)Terry P. Gould(Director)Wilbur H. Gantz III(Director)
Board seatJames N. Topper· per SEC Form D
HealthtechPhoenix, US
ARASH ARAGHI(Executive Officer, Director)DAVID JACOFSKY(Executive Officer, Director)PETER SLATE(Executive Officer)JOHN BROWN(Director)WARREN COHEN(Director)BRYAN WALL(Executive Officer, Director)
Board seatNathan Every· per SEC Form D · $14M raise · filed Dec 2016
Bellevue, US
Kelly Allison(Executive Officer)Scott Svenson(Executive Officer, Director, Promoter)
Board seatNader Naini· per SEC Form D · $35M raise · filed Mar 2016
BiotechSan Diego, US
Cam Garner(Treasurer)Theodore R. Schroeder(President and Chief Executive Officer)Cam Gallagher(Secretary)
Board seatPatrick Heron· per SEC Form D · $45.7M raise · filed Apr 2016
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.